Story is really important given pharma push to loosen U.S. Phase I trial regulations so U.S. can be more "competitive" with China.
Exclusive from Jason Mast and Brian Yang at @statnews.com who write "the disclosure raises concerns about the quality and transparency of China’s more lightly regulated pathway for drug trials." www.statnews.com/2026/08/05/c...